Taiwan based ACRO Biomedical Co., Ltd., the first company in the world to utilize "supercritical CO₂ extraction technology" on cleansing animal tissues and organs, is gradually showing impressive results on the global patent map.

In 2019, ACRO acquired two patents from Japan. One for the decellularized cartilage graft, and another for the decellularized cornea. The great news continues with ACRO acquiring patents from the USA and Korea successively for the decellularized cornea in March 2020.

ACRO has acquired patents from Taiwan, the USA, Japan, and Korea for the preparation of acellular corneas by utilizing supercritical CO₂ extraction technology. Patents from India, EU, Hong Kong, and mainland China are also on their way. The wish to benefit patients around the world with damaged cornea is very promising.

The advantages of ACRO's technology application are its high efficiency, low cost, time-saving, and when compared with other products of the same type that are decellularized with acid-base solutions or organic solvents, it greatly reduces the chance of allergy and immune rejection. It is a great help for the future development of the global regenerative medicine.